Wim van den Brink

Wim van den Brink
Born (1952-04-16) 16 April 1952 [1]
Hilversum, the Netherlands
Fields Psychiatry and addiction
Institutions Academic Medical Center, University of Amsterdam
Education M.D. VU University Amsterdam, PhD University of Groningen
Known for Neurobiology and treatment of addiction
Notable awards Marie Curie Award

Wim van den Brink (born 1952) is Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam.[2] He is also Director of the Amsterdam Institute for Addiction Research (AIAR)[3] and Scientific Director of the National Committee for Treatment of Heroin Addiction (CCBH) in Utrecht, the Netherlands.

He is the Chair of the Scientific Programme Committee of 26th, 27th, and 28th ECNP Congress, Europe’s largest meeting in applied and translational neuroscience.[4]

Career

Research focus/interests

Dr. van den Brink is one of the world’s established experts on the neurobiology and the pharmacological treatment of addiction. His work explores not only the neurobiological research and treatment development of addiction but also the implementation of treatments at the health-services level.[5]

Notable contributions to research

Van den Brink is recognized as the first to test and implement heroin-assisted treatment (HAT) and deep brain stimulation (DBS) in heroin dependent patients.[6]

Awards

Van den Brink has won the following awards for his work:[7]

Present and previous Appointments

Dr. van den Brink is currently Professor of Psychiatry and Addiction at the Academic Medical Center at the University of Amsterdam.[2] He is also Director of the Amsterdam Institute for Addiction Research (AIAR)[3] and Scientific Director of the National Committee for Treatment of Heroin Addiction (CCBH) in Utrecht, the Netherlands.[7]

Van den Brink was an Assistant Professor of Psychiatry and Addiction at the Academic Medical Center Groningen, the Netherlands, where he was also a senior researcher and a psychiatric resident. He also completed a fellowship in Psychiatric Epidemiology at Columbia University in New York.[7]

Positions of trust and research assessments

Dr. van den Brink is the Chair of the Scientific Programme Committee of 26th, 27th, and 28th ECNP Congress. He has been a member of the European College of Neuropsychopharmacology (ECNP) since 2003 and on the Executive Committee since 2010.[7]

Van den Brink is a member of the Scientific Advisory Board of the Swiss Research Institute of Public Health and Addiction. He is a member of the International Advisory Board of the European Graduate School in Addiction Research. He is the President of the International Collaboration on ADHD and Substance Abuse (ICASA).[7]

He is a member of many editorial boards, including Sucht, Addiction Biology, International Journal of Methods in Psychiatric Research, and Mind and Brain. He is editor of European Addiction Research. He is on the Editorial Advisory Board of Current Drug Abuse Reviews as well as the Methodological Advisor for the Netherlands Journal of Psychiatry.[7]

Publications

Van den Brink as published extensively, (co)authoring over 300 peer-reviewed articles.[7]

References

  1. ↑ Prof. dr. W. van den Brink, 1952 - at the UvA Album Academicum website.
  2. 1 2 "Prof. dr. W. van den Brink MD". www.amc.nl. Retrieved 6 July 2015.
  3. 1 2 "Van den Brink Group – Addiction". www.amcpsychiatrie.nl. Retrieved 6 July 2015.
  4. ↑ "The Executive Committee". www.ecnp.eu. Retrieved 6 July 2015.
  5. ↑ "Wim van den Brink". www.lebic-amc.nl. Retrieved 6 July 2015.
  6. ↑ Yan, Jun (6 February 2009). "Heroin-Assisted Treatment Helps Some Patients". psychnews.psychiatryonline.org. Retrieved 6 July 2015.
  7. 1 2 3 4 5 6 7 "Wim van den Brink, MD PhD" (PDF). www.ecnp.eu. Retrieved 6 July 2015.
This article is issued from Wikipedia - version of the 9/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.